## bs-3543R

## [ Primary Antibody ]

www.bioss.com.cn sales@bioss.com.cn techsupport@bioss.com.cn 400-901-9800

# phospho-NFKB p65 (Ser276) Rabbit pAb

DATASHEET -

Host: Rabbit Isotype: IgG

Clonality: Polyclonal

**GeneID:** 5970 **SWISS:** Q04206

Target: NFKB p65 (Ser276)

**Immunogen:** KLH conjugated Synthesised phosphopeptide derived from human

NFKBp65 around the phosphorylation site of Ser276: RP(p-S)DR.

Purification: affinity purified by Protein A

Concentration: 1mg/ml

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50%

Glycerol.

Shipped at 4°C. Store at -20°C for one year. Avoid repeated

freeze/thaw cycles.

**Background:** NF-kappa-B is a ubiquitous transcription factor involved in several biological processes. It is held in the cytoplasm in an inactive state by specific inhibitors. Upon degradation of the inhibitor, NF-kappa-B moves to the nucleus and activates transcription of specific genes. NF-kappa-B is composed of NFKB1 or NFKB2 bound to either REL, RELA, or RELB. The most abundant form of NF-kappa-B is NFKB1 complexed with the product of this gene, RELA. Four transcript variants encoding different isoforms have been found for

this gene. [provided by RefSeq, Sep 2011].

Applications: IHC-P (1:100-500)

IHC-F (1:100-500) **IF** (1:100-500)

Flow-Cyt (0.2µg /Test)

**ICC/IF** (1:100)

Reactivity: Human, Mouse, Rat

(predicted: Pig, Cow, Dog,

Horse)


Predicted 61 kDa

MW.:


Subcellular

Location: Cytoplasm ,Nucleus

## VALIDATION IMAGES




Paraformaldehyde-fixed, paraffin embedded (Rat urinary bladder): Antigen retrieval by  $microwave\ in\ sodium\ citrate\ buffer\ (pH6.0)\ ;$ Block endogenous peroxidase by 3% hydrogen peroxide for 30 minutes; Blocking buffer (3% BSA) at RT for 30min; Antibody incubation with (Phospho-NFKB p65(Ser276)) Polyclonal Antibody, Unconjugated (bs-3543R) at 1:400 overnight at 4°C, followed by conjugation to the secondary antibody (labeled with HRP) and DAB staining.




Blank control:A431. Primary Antibody (green line): Rabbit Anti-Phospho-NFKB p65 (Ser276) antibody (bs-3543R) Dilution: 1µg/10^6 cells; Isotype Control Antibody (orange line): Rabbit IgG . Secondary Antibody : Goat anti-rabbit IgG-



Tissue/cell:MCF7 cell; 4% Paraformaldehydefixed: Triton X-100 at room temperature for 20 min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Antibody incubation with (Phospho-NFKB p65 (Ser276)) polyclonal Antibody, Unconjugated (bs-2048R) 1:100, 90 minutes at 37°C; followed by a FITC conjugated Goat Anti-Rabbit IgG antibody at 37°C for 90 minutes, DAPI (blue, C02-04002) was used to stain the cell nuclei.



Blank control(blue): Jurkat cells(fixed with 2% paraformaldehyde (10 min), then permeabilized with 90% ice-cold methanol for 30 min on ice). Primary Antibody:Rabbit Anti-NFKB p65(Ser276)antibody antibody(bs-3543R),



Tissue/cell:Hela cell; 4% Paraformaldehydefixed: Triton X-100 at room temperature for 20 min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Antibody incubation with (Phospho-NFKB p65 (Ser276)) polyclonal Antibody, Unconjugated (bs-3543R) 1:100, 90 minutes at 37°C; followed by a FITC conjugated Goat Anti-Rabbit IgG antibody at 37°C for 90 minutes, DAPI (blue, C02-04002) was used to stain the cell nuclei.

FITC Dilution:  $1\mu g$  /test. Protocol The cells were fixed with 4% PFA ( $10\min$  at room temperature) and then permeabilized with 90% ice-cold methanol for  $20\min$  at -20%C. The cells were then incubated in 5%BSA to block nonspecific protein-protein interactions for  $30\min$  at room temperature. Cells stained with Primary Antibody for  $30\min$  at room temperature. The secondary antibody used for  $40\min$  at room temperature. Acquisition of 20,000 events was performed.

Dilution: 0.2µg in 100 µL 1X PBS containing 0.5% BSA; Isotype Control Antibody: Rabbit IgG(orange),used under the same conditions); Secondary Antibody: Goat anti-rabbit IgG-PE(white blue), Dilution: 1:200 in 1 X PBS containing 0.5% BSA.

### - SELECTED CITATIONS -

- [IF=40.73] Parker, Matthew, et al. "C11orf95-RELA fusions drive oncogenic NF-kB signalling in ependymoma." Nature (2014). IHC ;Human&Mouse. 24553141
- [IF=12.6] Yang Chuan. et al. An orally-administered nanotherapeutics with gold nanospheres supplying for rheumatoid arthritis therapy by re-shaping gut microbial tryptophan metabolism. J NANOBIOTECHNOL. 2025 Dec;23(1):1-22 IHC ;Mouse. 40414887
- [IF=10.383] Zhen Xu. et al. Green Biosynthesis of Silver Nanoparticles Using Aqueous Extracts of Ageratum Conyzoides and Their Anti-Inflammatory Effects. ACS APPL MATER INTER. 2023;XXXX(XXX):XXX-XXX WB; Mouse, Human. 36881383
- [IF=7.9] Kuangyang Yang. et al. Identification of Andrographolide as a novel FABP4 inhibitor for osteoarthritis treatment. PHYTOMEDICINE. 2023 Sep;118:154939 WB; Human. 37354697
- [IF=7.561] Sun J. et al. Plasma Exosomes Transfer miR-885-3p Targeting the AKT/NFkB Signaling Pathway to Improve the Sensitivity of Intravenous Glucocorticoid Therapy Against Graves Ophthalmopathy.. Front Immunol. 2022 Feb;13:819680-819680 WB; Mouse. 35265076